Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 2/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2668588 | 0.96 | ALOX5 (0.47) | ALOX5KDM5APHF8KDM2AHPGD | |
| SCHEMBL30296278 | 0.81 | ALOX5 (0.41) | ALOX5L3MBTL1MEN1KMT2A | |
| SCHEMBL21548898 | 0.81 | ALOX5 (0.41) | ALOX5L3MBTL1MEN1KMT2A | |
| SCHEMBL2497168 | 0.81 | ALOX5 (0.41) | ALOX5L3MBTL1MEN1KMT2A | |
| SCHEMBL27971919 | 0.79 | ADH1A (0.47) | ALOX5HSD11B1L3MBTL1MEN1KMT2A | |
| SCHEMBL1953627 | 0.78 | ALOX5 (0.45) | ALOX5L3MBTL1 | |
| SCHEMBL21197527 | 0.78 | ALOX5 (0.39) | ALOX5L3MBTL1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL27529969 | 0.78 | ADH1A (0.46) | ALOX5HSD11B1L3MBTL1MEN1KMT2A | |
| SCHEMBL9071877 | 0.76 | L3MBTL1 (0.41) | ALOX5HSD11B1L3MBTL1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL21198740 | 0.76 | ALOX5 (0.38) | ALOX5L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643397-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20150315157-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-11-05 | — | — | US | disclosed |
| US-20140336383-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-11-13 | — | — | US | disclosed |
| US-8815884-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140024666-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-23 | — | — | US | disclosed |
| US-8557834-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130072487-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-03-21 | — | — | US | disclosed |
| CN-101505752-B | Prolyl hydroxylase inhibitors | SMITHKLINE BEECHAM CORP | 2012-12-05 | — | — | CN | disclosed |
| CN-101505752-A | Prolyl hydroxylase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2009-08-12 | — | — | CN | disclosed |
| EP-2037922-A2 | PROLYL HYDROXYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007150011-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024666-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | ALOX5 1559/4885HSD11B1 980/4885KDM5A 432/4885 |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | ALOX5 1559/4885HSD11B1 980/4885KDM5A 432/4885 |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | ALOX5 1559/4885HSD11B1 980/4885KDM5A 432/4885 |
| US-20130072487-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | ALOX5 1559/4885HSD11B1 980/4885KDM5A 432/4885 |
| US-20140336383-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | ALOX5 1559/4885HSD11B1 980/4885KDM5A 432/4885 |
| US-20150315157-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | ALOX5 1559/4885HSD11B1 980/4885KDM5A 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.